CANY
CBAY

Caxton Associates (New York)’s Cymabay Therapeutics CBAY Stock Holding History

Caxton Associates (New York)’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,725
Closed -$224K – 690
2023
Q1 		$224K Sell
25,725
-47,924
-65% -$384K 0.03% 398
2022
Q4 		$462K Buy
73,649
+14,225
+24% +$54.1K 0.03% 256
2022
Q3 		$208K Sell
59,424
-45,778
-44% -$164K 0.03% 395
2022
Q2 		$310K Sell
105,202
-12,700
-11% -$30.3K 0.03% 380
2022
Q1 		$367K Buy
+117,902
New +$371K 0.03% 323

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Caxton Associates (New York)'s CBAY Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 25,725 shares — an estimated $224K sold.

Caxton Associates (New York) first reported a position in CBAY in Q1 2022 and held it in 5 quarters. The position peaked at $462K in Q4 2022. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 25,725 Cymabay Therapeutics shares in Q2 2023, an estimated $224K.
  • Caxton Associates (New York) first reported a position in Cymabay Therapeutics in Q1 2022 and held it in 5 quarters.
  • Caxton Associates (New York)'s Cymabay Therapeutics position peaked at $462K in Q4 2022.
  • 151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.